Cargando…
Priority-Setting for Novel Drug Regimens to Treat Tuberculosis: An Epidemiologic Model
BACKGROUND: Novel drug regimens are needed for tuberculosis (TB) treatment. New regimens aim to improve on characteristics such as duration, efficacy, and safety profile, but no single regimen is likely to be ideal in all respects. By linking these regimen characteristics to a novel regimen’s abilit...
Autores principales: | Kendall, Emily A., Shrestha, Sourya, Cohen, Ted, Nuermberger, Eric, Dooley, Kelly E., Gonzalez-Angulo, Lice, Churchyard, Gavin J., Nahid, Payam, Rich, Michael L., Bansbach, Cathy, Forissier, Thomas, Lienhardt, Christian, Dowdy, David W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5207633/ https://www.ncbi.nlm.nih.gov/pubmed/28045934 http://dx.doi.org/10.1371/journal.pmed.1002202 |
Ejemplares similares
-
Drivers and Trajectories of Resistance to New First-Line Drug Regimens for Tuberculosis
por: Shrestha, Sourya, et al.
Publicado: (2014) -
Development of new TB regimens: Harmonizing trial design, product registration requirements, and public health guidance
por: Lienhardt, Christian, et al.
Publicado: (2019) -
Reply to Pierce: Subclinical Tuberculosis: Some Flies in the Ointment
por: Kendall, Emily A., et al.
Publicado: (2021) -
World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update
por: Falzon, Dennis, et al.
Publicado: (2017) -
Advances in clinical trial design for development of new TB treatments: A call for innovation
por: Lienhardt, Christian, et al.
Publicado: (2019)